{"id":3752,"date":"2025-08-12T09:09:00","date_gmt":"2025-08-12T12:09:00","guid":{"rendered":"https:\/\/bionovis.com.br\/medicines\/adalimumabe\/"},"modified":"2025-12-02T15:58:16","modified_gmt":"2025-12-02T18:58:16","slug":"adalimumab","status":"publish","type":"page","link":"https:\/\/bionovis.com.br\/en\/medicines\/adalimumab\/","title":{"rendered":"Adalimumab"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Adalimumab <\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Home<\/a><\/span><\/span><\/p>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Anti-TNF monoclonal antibody indicated for rheumatoid arthritis, psoriasis, Crohn\u2019s disease, and ulcerative colitis.<\/b><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t
\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Adalimumab <\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Active Ingredient: <\/font>Adalimumab \n<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Indications for Adalimumab:<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

This medication is indicated for the treatment of:

ADULTS:<\/strong>

Rheumatoid Arthritis<\/strong>
Adalimumab is indicated to reduce the signs and symptoms, induce a clinical response and major clinical remission, inhibit the progression of structural damage, and improve physical function in adult patients with moderate to severe active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARD).
Adalimumab is also indicated for the treatment of severe, active, and progressive rheumatoid arthritis in patients who have not previously been treated with methotrexate.\u00a0 Adalimumab may be used as monotherapy or in combination with methotrexate or another DMARD.

Psoriatic Arthritis<\/strong>
Adalimumab is indicated to reduce the signs and symptoms of psoriatic arthritis.\u00a0 Adalimumab may be used as monotherapy or in combination with disease-modifying antirheumatic drugs (DMARDs).\u00a0

Axial Spondyloarthritis <\/strong>
\u2013 Ankylosing Spondylitis (AS)<\/strong>
Adalimumab is intended for the treatment of active ankylosing spondylitis in patients with an inadequate response to conventional therapy.

\u2013 Non-radiographic axial spondyloarthritis (axial spondyloarthritis without radiographic evidence of AS)<\/strong>
Adalimumab is indicated for the treatment of adult patients with severe axial spondyloarthritis without radiographic evidence of AS who have objective signs of inflammation (elevated CRP and\/or MRI findings) and who have had an inadequate response or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).

Crohn\u2019s Disease<\/strong>
Adalimumab is indicated to reduce the signs and symptoms, induce and maintain clinical remission in adult patients with moderate to severe active Crohn\u2019s Disease who have had an inadequate response to conventional therapy.
Adalimumab is also indicated to reduce signs and symptoms and induce clinical remission in patients who have become unresponsive or intolerant to infliximab.

Ulcerative Colitis or Ulcerative Rectocolitis<\/strong>
Adalimumab is indicated for the treatment of moderate to severe active ulcerative colitis or ulcerative rectocolitis in adult patients who have had an inadequate response to conventional therapy, including corticosteroids and\/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have contraindications to these therapies.
Adalimumab induces and maintains mucosal healing in these patients, reduces disease-related hospitalization and its causes, and improves quality of life. Corticosteroid use may be reduced or discontinued.

Plaque Psoriasis<\/strong>
Adalimumab is intended for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are indicated for systemic therapy.

Hidradenitis Suppurativa<\/strong>
Adalimumab is indicated to reduce the signs and symptoms of moderate to severe active hidradenitis suppurativa in adult patients for whom antibiotic therapy has been inadequate, including treatment of inflammatory lesions and prevention of worsening abscesses and fistulas.

Uveitis<\/strong>
Adalimumab is indicated for the treatment of non-infectious intermediate, posterior, or panuveitis in adult patients who have had an inadequate response to corticosteroids, who require corticosteroid-sparing therapy (corticosteroid reduction\/withdrawal), or for whom corticosteroid use is inappropriate.

PEDIATRIC USE:<\/strong>

Polyarticular Juvenile Idiopathic Arthritis <\/strong>
Adalimumab, in combination with methotrexate, is indicated to reduce the signs and symptoms of moderate to severe active polyarticular juvenile idiopathic arthritis in pediatric patients over 2 years of age who have had an inadequate response to at least one DMARD.\u00a0 Adalimumab may be used as monotherapy in individuals who are intolerant to methotrexate or when concomitant use with methotrexate is inappropriate.

Enthesitis-Related Arthritis<\/strong>
Adalimumab is indicated for the treatment of enthesitis-related arthritis in pediatric patients over 6 years of age who have had an inadequate response to or are intolerant to conventional therapy.

Crohn\u2019s Disease <\/strong>
Adalimumab is indicated to reduce signs and symptoms, induce and maintain clinical remission in pediatric patients over 6 years of age with moderate to severe active Crohn\u2019s Disease who have had an inadequate response to conventional therapy.

Ulcerative Colitis or Pediatric Ulcerative Rectocolitis <\/strong>
Adalimumab is indicated for the treatment of moderate to severe active ulcerative colitis or ulcerative rectocolitis in pediatric patients (6 years of age and older) who have had an inadequate response to conventional therapy, including corticosteroids and\/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications to these therapies.

Pediatric Uveitis<\/strong>
Adalimumab is indicated for the treatment of non-infectious, chronic, anterior uveitis in pediatric patients aged 2 years and older who have had an inadequate response to or are intolerant to conventional therapy, or when conventional therapy is inappropriate.<\/p>

Hidradenitis Suppurativa in Adolescents<\/strong><\/p>

Adalimumab is indicated for the treatment of moderate to severe active hidradenitis suppurativa (acne inversa) in adolescents aged 12 years and older who have had an inadequate response to conventional systemic therapy for hidradenitis suppurativa (HS).

<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Specifications<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\n\t\t\t\t\t\t
\n\t\t\t\t\n\t\t\t\t<\/i>\t\t\t\t<\/span>\n\t\t\t<\/div>\n\t\t\t\n\t\t\t\t\t\t
\n\n\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tType of medication:\t\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/h3>\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\tBiologic; monoclonal antibody; immunosuppressant.\t\t\t\t\t<\/p>\n\t\t\t\t\n\t\t\t<\/div>\n\t\t\t\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\n\t\t\t\t\t\t
\n\t\t\t\t\n\t\t\t\t<\/i>\t\t\t\t<\/span>\n\t\t\t<\/div>\n\t\t\t\n\t\t\t\t\t\t
\n\n\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tClass\/Main Target: \t\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/h3>\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\tAnti-TNF.\t\t\t\t\t<\/p>\n\t\t\t\t\n\t\t\t<\/div>\n\t\t\t\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\n\t\t\t\t\t\t
\n\t\t\t\t\n\t\t\t\t<\/i>\t\t\t\t<\/span>\n\t\t\t<\/div>\n\t\t\t\n\t\t\t\t\t\t
\n\n\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tTherapeutic Area (MoA):\t\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/h3>\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\tImmunology.\t\t\t\t\t<\/p>\n\t\t\t\t\n\t\t\t<\/div>\n\t\t\t\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\n\t\t\t\t\t\t
\n\t\t\t\t\n\t\t\t\t<\/i>\t\t\t\t<\/span>\n\t\t\t<\/div>\n\t\t\t\n\t\t\t\t\t\t
\n\n\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tPrescription required?\t\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/h3>\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\tSale by prescription only.\t\t\t\t\t<\/p>\n\t\t\t\t\n\t\t\t<\/div>\n\t\t\t\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\n\t\t\t\n\t\t\t\t\t\tThe responsible use of medications is essential for treatment safety and efficacy. Self-medication may mask symptoms, cause adverse effects, and compromise health. Prescription medicines must be used only under the guidance of a qualified healthcare professional.<\/span>\n\t\t\t\n\t\t\t\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

Adalimumab Anti-TNF monoclonal antibody indicated for rheumatoid arthritis, psoriasis, Crohn\u2019s disease, and ulcerative colitis. Adalimumab Active Ingredient: Adalimumab Indications for Adalimumab: This medication is indicated for the treatment of: ADULTS: Rheumatoid Arthritis Adalimumab is indicated to reduce the signs and symptoms, induce a clinical response and major clinical remission, inhibit the progression of structural damage, […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":2944,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_header_footer","meta":{"footnotes":""},"class_list":["post-3752","page","type-page","status-publish","hentry"],"yoast_head":"\nAdalimumab - Bionovis<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bionovis.com.br\/medicamentos\/adalimumabe\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Adalimumab\" \/>\n<meta property=\"og:description\" content=\"Adalimumab Anti-TNF monoclonal antibody indicated for rheumatoid arthritis, psoriasis, Crohn\u2019s disease, and ulcerative colitis. Adalimumab Active Ingredient: Adalimumab Indications for Adalimumab: This medication is indicated for the treatment of: ADULTS: Rheumatoid Arthritis Adalimumab is indicated to reduce the signs and symptoms, induce a clinical response and major clinical remission, inhibit the progression of structural damage, […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bionovis.com.br\/medicamentos\/adalimumabe\/\" \/>\n<meta property=\"og:site_name\" content=\"Bionovis\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-02T18:58:16+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/bionovis.com.br\/medicamentos\/adalimumabe\/\",\"url\":\"https:\/\/bionovis.com.br\/medicamentos\/adalimumabe\/\",\"name\":\"Adalimumab - Bionovis\",\"isPartOf\":{\"@id\":\"https:\/\/bionovis.com.br\/#website\"},\"datePublished\":\"2025-08-12T12:09:00+00:00\",\"dateModified\":\"2025-12-02T18:58:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/bionovis.com.br\/medicamentos\/adalimumabe\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/bionovis.com.br\/medicamentos\/adalimumabe\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/bionovis.com.br\/medicamentos\/adalimumabe\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/bionovis.com.br\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Medicines\",\"item\":\"https:\/\/bionovis.com.br\/medicamentos\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Adalimumab\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/bionovis.com.br\/#website\",\"url\":\"https:\/\/bionovis.com.br\/\",\"name\":\"Bionovis\",\"description\":\"A INOVA\u00c7\u00c3O NASCE AQUI\",\"publisher\":{\"@id\":\"https:\/\/bionovis.com.br\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/bionovis.com.br\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/bionovis.com.br\/#organization\",\"name\":\"Bionovis\",\"url\":\"https:\/\/bionovis.com.br\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/bionovis.com.br\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/bionovis.com.br\/wp-content\/uploads\/2025\/04\/BIONOVIS.svg\",\"contentUrl\":\"https:\/\/bionovis.com.br\/wp-content\/uploads\/2025\/04\/BIONOVIS.svg\",\"caption\":\"Bionovis\"},\"image\":{\"@id\":\"https:\/\/bionovis.com.br\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Adalimumab - Bionovis","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bionovis.com.br\/medicamentos\/adalimumabe\/","og_locale":"en_US","og_type":"article","og_title":"Adalimumab","og_description":"Adalimumab Anti-TNF monoclonal antibody indicated for rheumatoid arthritis, psoriasis, Crohn\u2019s disease, and ulcerative colitis. Adalimumab Active Ingredient: Adalimumab Indications for Adalimumab: This medication is indicated for the treatment of: ADULTS: Rheumatoid Arthritis Adalimumab is indicated to reduce the signs and symptoms, induce a clinical response and major clinical remission, inhibit the progression of structural damage, […]","og_url":"https:\/\/bionovis.com.br\/medicamentos\/adalimumabe\/","og_site_name":"Bionovis","article_modified_time":"2025-12-02T18:58:16+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/bionovis.com.br\/medicamentos\/adalimumabe\/","url":"https:\/\/bionovis.com.br\/medicamentos\/adalimumabe\/","name":"Adalimumab - Bionovis","isPartOf":{"@id":"https:\/\/bionovis.com.br\/#website"},"datePublished":"2025-08-12T12:09:00+00:00","dateModified":"2025-12-02T18:58:16+00:00","breadcrumb":{"@id":"https:\/\/bionovis.com.br\/medicamentos\/adalimumabe\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bionovis.com.br\/medicamentos\/adalimumabe\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/bionovis.com.br\/medicamentos\/adalimumabe\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bionovis.com.br\/en\/"},{"@type":"ListItem","position":2,"name":"Medicines","item":"https:\/\/bionovis.com.br\/medicamentos\/"},{"@type":"ListItem","position":3,"name":"Adalimumab"}]},{"@type":"WebSite","@id":"https:\/\/bionovis.com.br\/#website","url":"https:\/\/bionovis.com.br\/","name":"Bionovis","description":"A INOVA\u00c7\u00c3O NASCE AQUI","publisher":{"@id":"https:\/\/bionovis.com.br\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/bionovis.com.br\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/bionovis.com.br\/#organization","name":"Bionovis","url":"https:\/\/bionovis.com.br\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/bionovis.com.br\/#\/schema\/logo\/image\/","url":"https:\/\/bionovis.com.br\/wp-content\/uploads\/2025\/04\/BIONOVIS.svg","contentUrl":"https:\/\/bionovis.com.br\/wp-content\/uploads\/2025\/04\/BIONOVIS.svg","caption":"Bionovis"},"image":{"@id":"https:\/\/bionovis.com.br\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/bionovis.com.br\/en\/wp-json\/wp\/v2\/pages\/3752","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bionovis.com.br\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/bionovis.com.br\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/bionovis.com.br\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bionovis.com.br\/en\/wp-json\/wp\/v2\/comments?post=3752"}],"version-history":[{"count":0,"href":"https:\/\/bionovis.com.br\/en\/wp-json\/wp\/v2\/pages\/3752\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/bionovis.com.br\/en\/wp-json\/wp\/v2\/pages\/2944"}],"wp:attachment":[{"href":"https:\/\/bionovis.com.br\/en\/wp-json\/wp\/v2\/media?parent=3752"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}